Nature Communications · 2022 · 54 citations · 38 references
MedicineCancer BiologyOncologyChemotherapyMolecular OncologyTumor ProgressionCancer ProgressionColorectal CancerMalignant NeoplasmsMolecular Tumor ProfilingPersonalized Cancer TherapyTumorigenicity AssessmentCancer Stem-like CellsFetal MorphogenesisMetastatic BiomarkersOrganoidsPatient Outcome PredictionPatient-derived OrganoidsSublethal ToxicityTp53 Mutations
Current therapy against colorectal cancer (CRC) is based on DNA-damaging agents that remain ineffective in a proportion of patients. Whether and how non-curative DNA damage-based treatment affects tumor cell behavior and patient outcome is primarily unstudied. Using CRC patient-derived organoids (PDO)s, we show that sublethal doses of chemotherapy (CT) does not select previously resistant tumor populations but induces a quiescent state specifically to TP53 wildtype (WT) cancer cells, which is linked to the acquisition of a YAP1-dependent fetal phenotype. Cells displaying this phenotype exhibit high tumor-initiating and metastatic activity. Nuclear YAP1 and fetal traits are present in a proportion of tumors at diagnosis and predict poor prognosis in patients carrying TP53 WT CRC tumors. We provide data indicating the higher efficacy of CT together with YAP1 inhibitors for eradication of therapy resistant TP53 WT cancer cells. Together these results identify fetal conversion as a useful biomarker for patient prognosis and therapy prescription.
38
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Sendurai A. Mani, Wenjun Guo, Mai-Jing Liao et al. · Cell · 2008 · 8.7K citations · Full text
The consensus molecular subtypes of colorectal cancer
Justin Guinney, Rodrigo Dienstmann, Xin Wang et al. · Nature Medicine · 2015 · 5.3K citations · Full text
Senolytics improve physical function and increase lifespan in old age
Ming Xu, Tamar Pirtskhalava, Joshua N. Farr et al. · Nature Medicine · 2018 · 2.2K citations